[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroprotection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroprotection":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100617772","evaluation-of-brudyglauco-dha--citicoline-in-patients-with-glaucoma-100617772",false,"NCT07322965","Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","Evaluation of the Effect of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","BRUDYGLAUCO","Inclusion Criteria:\n\n1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:\n\n   Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.\n\n   Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.\n2. At least 4 reliable visual field (VF) tests before study enrollment.\n3. Age between 50 and 75 years.\n4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye.\n\nExclusion Criteria:\n\n1. Use of any vitamin or nutraceutical supplement in the month prior to screening.\n2. Any condition that could alter visual field testing, including:\n\n   Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.\n3. Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline).\n4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study.\n5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.","ALL","50 Years","75 Years",{"count":21,"type":22},108,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.\n\nThis is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.\n\nThe trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.\n\nThe results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.",[28,29,30],"Glaucoma","Primary Open Angle Glaucoma (POAG)","Neuroprotection",[32,33,30,34,35,36,37,38,39,40],"glaucoma","Primary Open-Angle Glaucoma (POAG)","Visual Field","DHA (Docosahexaenoic Acid)","Citicoline","Nutritional Supplement","Clinical Trial","Randomized Controlled Trial (RCT)","Visual Function","RECRUITING","2026-01-12",{"date":44,"type":45},"2026-01-14","ACTUAL",{"date":47,"type":45},"2025-04-01",{"date":49,"type":22},"2027-05-30",{"name":51,"class":52},"Institut Catala de Retina","OTHER",2,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100413542","intra-arterial-neuroprotective-strategy-for-ischemic-stroke-patients-with-no-reperfusion-therapy-insist-nrt-100413542","NCT04664946","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Major neurologic deficits: 6≤NIHSS≤20;\n3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);\n4. Premorbid mRS 0 or 1;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Patients who underwent intravenous thrombolysis or Endovascular treatment;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\\u003C80000\u002Fmm3;\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n6. Unsuitable for this clinical studies assessed by researcher.","18 Years",{"count":63,"type":22},30,[25],"To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.",[67,30],"Ischemic Stroke","2025-08-20",{"date":70,"type":45},"2025-08-21",{"date":72,"type":45},"2020-12-01",{"date":74,"type":22},"2026-05-01",{"name":76,"class":52},"Hui-Sheng Chen",1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":114},"100379195","phase-3-cerebrum-and-cardiac-protection-with-allopurinol-in-neonates-with-critical-congenital-heart-disease-requiring-cardiac-surgery-with-cardiopulmonary-bypass-100379195","NCT04217421","Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass","CRUCIAL","Inclusion Criteria:\n\n* Neonates with a prenatally or postnatally confirmed diagnosis of CCHD requiring (anticipated) cardiac surgery with CPB within the first 4 weeks of life.\n* Informed consent provided by both parents.\n\nExclusion Criteria:\n\n* Inability to enroll the patient before the start of delivery in case of prenatal diagnosis, or 24 hours before surgery in case of postnatal diagnosis.\n* Doubt whether the aortic arch anomaly before birth requires cardiac surgery with CPB in the neonatal period.\n* Gestational age below 36 weeks and\u002For birth weight less than 2000 gram.\n* Surgery not requiring cardiopulmonary bypass.\n* Decision for \"comfort care only\".","1 Month",{"count":87,"type":22},236,[89],"PHASE3","Neurodevelopmental impairment due to delayed brain development and brain injury is a fundamental problem in children with critical congenital heart disease (CCHD). Significant longterm motor-, cognitive-, and behavioral problems are the result of early postnatally and perioperatively induced brain injury. Allopurinol, a xanthine oxidase inhibitor, prevents the formation of toxic free oxygen radicals, thereby limiting hypoxia-reperfusion damage. Both animal and neonatal studies suggest that administration of allopurinol reduces hypoxic-ischemic brain injury, is cardioprotective, and safe. This study aims to evaluate the efficacy and safety of allopurinol administered early postnatally and perioperatively in children with a CCHD requiring cardiac surgery with cardiopulmonary bypass.",[92,30],"Congenital Heart Disease in Children",[94,30,95,96,97,98,99,100,101,102,103,104],"Congenital Heart Disease","Allopurinol","Brain injury","Cardiopulmonary bypass","Brain function","Brain oxygenation","Cardiac function","Neurodevelopmental outcome","Cardiac surgery","Hypoxic-ischemic brain injury","Neonates","2024-05-13",{"date":107,"type":45},"2024-05-16",{"date":109,"type":45},"2020-02-14",{"date":111,"type":22},"2028-12-31",{"name":113,"class":52},"dr. M.J.N.L. Benders",4]